NEW GEL DELIVERY SYSTEM FOR TREATING SOLID CANCER TUMORS

-

 

NEW GEL DELIVERY SYSTEM FOR TREATING SOLID CANCER TUMORS

    


Intratumoral therapy -- in which cancer drugs are injected directly into tumors -- is a promising treatment option for solid cancers but has shown limited success in clinical trials due to an inability to precisely deliver the drug and because most immunotherapies quickly dissipate from the site of injection. Collaborating with colleagues at the Koch Institute for Integrative Cancer Research, a team of researchers from Mass General Brigham has developed a gel delivery system that overcomes these challenges. The gel is injectable but solidifies upon delivery, contains an imaging agent for visualization under a CT scan, and can hold a high drug concentration for slow, controlled release.

In a paper published in Advanced Healthcare Materials, the team reports that using gel-delivered imiquimod (an immune-stimulating drug) in combination with checkpoint inhibitor therapy-induced tumor regression and increased survival in mouse models of colon and breast cancer that are usually resistant to checkpoint inhibitor therapy. The treatment also trained the immune system to detect and attack distant tumors that were not directly treated, suggesting that it is a helpful therapy for metastatic cancers.

"This gel tackles the two problems with existing attempts at making intratumoral cancer immunotherapy: making the therapy visible and practical so that interventional radiologists can confirm delivery, and making sure the drug actually stays in the region of interest," said Avik Som, MD, Ph.D., of the Department of Radiology at Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system. "When we inject this gel into a tumor, we're able to teach the immune system to recognize the cancer and trigger it to attack not only the site where the gel was injected but also other areas in the body where the same cancer may be hiding."

The research team, consisting of engineers and medical professionals, first developed and optimized the gel-delivery system in the lab by tweaking the gel's chemical structure. One key aspect of the gel's design was that it needed to shift from liquid at room temperature to make it injectable to solid at body temperature inside the tumor to form a drug-releasing depot while retaining drug encapsulation and delivery capability and carrying sufficient imaging agent.

After optimizing the gel in the lab, the team tested its ability to treat mouse colon and breast cancer models, usually resistant to immunotherapy. To do this, they used the gel to deliver imiquimod, an FDA-approved immune-stimulating drug, in combination with checkpoint inhibitor therapy. Each mouse had two tumors of the same type. Still, the researchers only treated one tumor per mouse, allowing them to test the gel's ability to stimulate local and systemic immunity.

They showed that treating with gel-delivered imiquimod in combination with checkpoint inhibitor therapy improved survival in both cancer models. The treatment resulted in an all-or-nothing response -- mice that responded to the treatment showed complete regression of both the treated tumor and a distantly located tumor (a metastasis model). In contrast, non-responders showed no regression at either site. For the colon cancer model, 46% (6/13) survived when the checkpoint inhibitor therapy was combined with gel-delivered imiquimod. For the breast cancer model, 20% (3/15) survived when treated with the combined therapies.

"These two tumors remain challenging to treat today, even though immunotherapies are transforming how we think about treatment," said co-corresponding author Giovanni Traverso, MB, PhD, MBBCH, Department of Medicine at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system and an associate professor in the Department of Mechanical Engineering at MIT. "The fact that we were able to induce responses in distant tumors in these colon and breast cancer models was a big win."

The researchers are keen to move this technology to the clinic, but it will first need to go through more rounds of testing for safety. They also plan to test its efficacy with a broader panel of drugs.

"This is an early proof of concept, but we're all actively working together to try and get these technologies to patients," said Eric Wehrenberg-Klee, MD, assistant radiologist in the Department of Radiology at Massachusetts General Hospital and one of the study's first authors. "There's quite a bit of benefit to be gained by being able to treat patients with a single injection, and we think this technology has the potential to help with cancers that are currently challenging to treat."

Comments

Post a Comment

Popular posts from this blog

PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY

-
Image
  PEOPLE WITH OBESITY BURN LESS CALORIES DURING THE DAY Building on prior studies with healthy-weight participants, the new research includes different body sizes.         New research indicates that weight influences how and when bodies burn energy. An Oregon Health & Science University study published in the journal  Obesity  found people who have a healthy weight use more energy during the day, when most people are active and eat, while those who are obese spend more energy during the night when most people sleep. The study also found that during the day, those with obesity have higher levels of the hormone insulin -- a sign that the body is working harder to use glucose, an energy-packed sugar. "It was surprising to learn how dramatically the timing of when our bodies burn energy differed in those with obesity," said the study's first author, Andrew McHill, Ph.D., an assistant professor at the OHSU School of Nursing and the Oregon Institute of ...
Read more

WHAT CAUSES ITCHING, AND WHAT STOPS IT?

-
Image
  WHAT CAUSES ITCHING, AND WHAT STOPS IT?         It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a severe health problem. How does the body know when to stop? Scientists at UC San Francisco are getting close to an answer. In a breakthrough that could transform how doctors treat conditions from eczema to allergies, they have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation. The findings, published on October 13th in  Science Immunology , lay the groundwork for a new generation of drugs that interact more intelligently with the body's innate self-regulating ability. Previous approaches suggested that IL-31 signals itch and promotes skin inflammation. However, the UCSF team discovered that nerve cells, or neurons, that respond to IL-31, triggering a scratch, also prevent immune cells from overreacting and causing more ...
Read more

A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY

-
Image
  A VEGAN DIET IMPROVES CARDIOVASCULAR HEALTH, ACCORDING TO A NEW STUDY         In a study with 22 pairs of identical twins, Stanford Medicine researchers and their colleagues have found that a vegan diet improves cardiovascular health in as little as eight weeks. Although it's well-known that eating less meat improves cardiovascular health, diet studies often need to be enhanced by genetic differences, upbringing, and lifestyle choices. By studying identical twins, however, the researchers were able to control for genetics and limit the other factors, as the twins grew up in the same households and reported similar lifestyles. "Not only did this study provide a groundbreaking way to assert that a vegan diet is healthier than the conventional omnivore diet, but the twins were also a riot to work with," said Christopher Gardner, Ph.D., the Rehnborg Farquhar Professor and a professor of medicine. "They dressed the same, they talked the same, and they had a banter ...
Read more